prof. dr. E.M.D. (Ed) Schuuring
Professor of Molecular Oncological Pathology
Telephone:
E-mail:
e.schuuring umcg.nl
Field/Discipline
Expertise
Senior Clinical Scientist in Molecular Pathology
Other positions
Head of the Laboratory for Molecular Pathology at the UMCG
Senior Clinical Scientist in Molecular Pathology (Klinisch Moleculair Bioloog in de Pathologie)
Clinical Scientist in Molecular Pathology for Stichting Pathologie Friesland in Leeuwarden, Martini Ziekenhuis in Groningen, Pathologie Treant Zorggroep Bethesda Hospital in Hoogeveen and ADCNV lab in Curacao
Official instructor for educating and training of KMBP (clinical scientist in molecular pathology)
Member (past-president) of section Clinical Molecular and Experimental Pathology of the Dutch Society of Pathology
Member of the committee on “Revision of Onco-guidelines for NSCLC” (2019-2020)
Member of the committee on cervical cancer primary hrHPVpopulation-based screening program and responsible Clinical Scientific in Molecular Pathology for quality at UMCG screeningcenter
Active member of board in PATH and COIN programs
Senior expert/advisor on Molecular Pathology for ZIN/VWS, insurrance-companies, missiePTO, IKNL-platform CUP
Member of committee cieBOD (commissie BeOordeling Diagnostiek)
Member Redactieraad of Esculaap Media bv Journal in Dutch “Longkanker”
Referent for LongkankerNederland, KankerNL and Thuisarts websites with information for patients regarding DNA testing in cancer patients
Between 2012-2020 (31-12-2020): from commercial partners he received honoraria for expertise or scientific advisory board/consultancy (on request): MSD/Merck, AstraZeneca, Roche, Pfizer, Novartis, Bayer, BMS, Lilly, Amgen, Qiagen, BioCartis, Illumina, Agena Bioscience, CC Diagnostics, QCMD, ESP, IQNPATH, Cancer-ID, Janssen Cilag (Johnson&Johnson), Diaceutics; Speaker’s fee from Agena Bioscience, Bio-Rad, Abbott, Novartis, Roche, Biocartis, Illumina, Pfizer, Astrazeneca; Grants/Sponsoring from Abbott, MDXHealth/Oncomethylome, Pfizer, Biocartis, Cancer-ID, BMS, Astrazeneca, Invitae/Archer, Bayer, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, Boehringer Ingelheim, Qiagen, Promega, TATAA (all above-mentioned fee transferred to UMCG); Travel reimbursements from Agena Bioscience, BioRad, Illumina, Abbott, Roche and Hologic.
Bestuurslid van cieKNT (commissie Klinisch Noodzakelijke Targets)
Bestuurslid van cieTripartite
Member of European Society of Pathology (ESP), member ESP-workinggroup Molecular Pathology, member of ESP/QUip (QC-ringstudies on NSCLC and cfDNA (2012-now)
Executive board member of European Liquid Biopsy Society, co-lead of ELBS-ctDNA workinggroup
Bestuurslid (en mede-oprichter) van NVVP-registratiecommissie voor KMBPio (2011-2025)
Executive board member (and founder) of the European Master Molecular Pathology
Senior Clinical Scientist in Molecular Pathology (Klinisch Moleculair Bioloog in de Pathologie)
Clinical Scientist in Molecular Pathology for Stichting Pathologie Friesland in Leeuwarden, Martini Ziekenhuis in Groningen, Pathologie Treant Zorggroep Bethesda Hospital in Hoogeveen and ADCNV lab in Curacao
Official instructor for educating and training of KMBP (clinical scientist in molecular pathology)
Member (past-president) of section Clinical Molecular and Experimental Pathology of the Dutch Society of Pathology
Member of the committee on “Revision of Onco-guidelines for NSCLC” (2019-2020)
Member of the committee on cervical cancer primary hrHPVpopulation-based screening program and responsible Clinical Scientific in Molecular Pathology for quality at UMCG screeningcenter
Active member of board in PATH and COIN programs
Senior expert/advisor on Molecular Pathology for ZIN/VWS, insurrance-companies, missiePTO, IKNL-platform CUP
Member of committee cieBOD (commissie BeOordeling Diagnostiek)
Member Redactieraad of Esculaap Media bv Journal in Dutch “Longkanker”
Referent for LongkankerNederland, KankerNL and Thuisarts websites with information for patients regarding DNA testing in cancer patients
Between 2012-2020 (31-12-2020): from commercial partners he received honoraria for expertise or scientific advisory board/consultancy (on request): MSD/Merck, AstraZeneca, Roche, Pfizer, Novartis, Bayer, BMS, Lilly, Amgen, Qiagen, BioCartis, Illumina, Agena Bioscience, CC Diagnostics, QCMD, ESP, IQNPATH, Cancer-ID, Janssen Cilag (Johnson&Johnson), Diaceutics; Speaker’s fee from Agena Bioscience, Bio-Rad, Abbott, Novartis, Roche, Biocartis, Illumina, Pfizer, Astrazeneca; Grants/Sponsoring from Abbott, MDXHealth/Oncomethylome, Pfizer, Biocartis, Cancer-ID, BMS, Astrazeneca, Invitae/Archer, Bayer, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, Boehringer Ingelheim, Qiagen, Promega, TATAA (all above-mentioned fee transferred to UMCG); Travel reimbursements from Agena Bioscience, BioRad, Illumina, Abbott, Roche and Hologic.
Bestuurslid van cieKNT (commissie Klinisch Noodzakelijke Targets)
Bestuurslid van cieTripartite
Member of European Society of Pathology (ESP), member ESP-workinggroup Molecular Pathology, member of ESP/QUip (QC-ringstudies on NSCLC and cfDNA (2012-now)
Executive board member of European Liquid Biopsy Society, co-lead of ELBS-ctDNA workinggroup
Bestuurslid (en mede-oprichter) van NVVP-registratiecommissie voor KMBPio (2011-2025)
Executive board member (and founder) of the European Master Molecular Pathology
| Last modified: | 18 August 2025 9.50 p.m. |